|
|
Article: New Clinical Trial Data Showed the Addition of INTEGRILIN(R) (Eptifibatide) Injection Achieved Superior Platelet Inhibition and Less Heart Muscle Damage When Compared to a Commonly Used Antiplatelet Regimen Alone.
- Article from:
- PR Newswire
- Article date:
- November 8, 2004
CopyrightCOPYRIGHT 2004 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Millennium Pharmaceuticals, Inc. has announced that in the CLEAR Platelets (Clopidogrel Loading with Eptifibatide to Arrest the Reactivity of Platelets) trial, the addition of INTEGRILIN, a potent glycoprotein (GP) IIb-IIIa inhibitor, to a commonly used antiplatelet regimen provided superior platelet inhibition and prevention of heart muscle damage associated with elective coronary stenting in the low-to-moderate risk study patients. Damage to heart muscle has been linked to mortality.(1) Results from CLEAR Platelets were presented on Sunday, November 7, 2004 at the 2004 American Heart Association Scientific Sessions meeting in New Orleans.
(Logo: ...